| Literature DB >> 28093982 |
Agnieszka Jankowska1, Artur Swierczek2, Grazyna Chlon-Rzepa1, Maciej Pawlowski1, Elzbieta Wyska2.
Abstract
Phosphodiesterase 7 (PDE7) is an intracellular enzyme that specifically hydrolyzes the second messenger, cyclic-3',5'-adenosine monophosphate (cAMP), into inactive noncyclic nucleotide, 5'-AMP. To date, many structurally diverse compounds with PDE7 inhibitory properties have been described, including selective PDE7 inhibitors, dual PDE4/PDE7, PDE7/PDE8, and PDE7/GSK-3 inhibitors, and non-selective PDE inhibitors with high affinity for PDE7. Inhibitors of PDE7 have provided beneficial effects in animal models of inflammatory and neurological disorders, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and many others. This review is a comprehensive summary of the current state-of-the-art in the field of design and synthesis of PDE7 inhibitors, their physicochemical properties, biological evaluation, and structure-activity relationships as well as it highlights the updated evidence for a potential therapeutic utility of these compounds. Moreover, new approaches to obtain more effective and safer PDE7 inhibitors than those available now are presented. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.Entities:
Keywords: PDE7 inhibitors; SAR exploration; allosteric modulators; dual inhibitors; immunological diseases; inflammation; neurologicalzzm321990diseases
Mesh:
Substances:
Year: 2017 PMID: 28093982 DOI: 10.2174/0929867324666170116125159
Source DB: PubMed Journal: Curr Med Chem ISSN: 0929-8673 Impact factor: 4.530